Skip to content

One Touch® Verio®IQ European Clinical Outcomes Study

One Touch® Verio®IQ European Clinical Outcomes Study

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01631643
Enrollment
0
Registered
2012-06-29
Start date
2012-12-31
Completion date
2013-06-30
Last updated
2012-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

Blood glucose monitor, Pattern management, Pattern guide, Education

Brief summary

Evaluation of the clinical benefits of One Touch VerioIQ system.

Detailed description

Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.

Interventions

BGM with pattern alert technology and with associated pattern guide

Sponsors

LifeScan
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* male or female at least 18 to 80 years old * ADA guidelines for FPG and PPG appropriate * A1C greater or equal to 8.0% and less than or equal to 10.5% * lab A1C greater than or equal to 8.0% in the last 6-12mths * Diagnosed with type 1 or 2 in at least last 1 year * on stable dose of OADs for at least 3mths prior to screening * willingness to test 7 BGM tests per day * willing to remain on same therapy as baseline (MDI) for duration of study

Exclusion criteria

* unlikely to be compliant to study procedures * has or has currently used One Touch VerioIQ * Is on fixed doses of insulin for MDI therapy

Design outcomes

Primary

MeasureTime frameDescription
Change in A1C from baseline to week 2424 weeksA1C (also known as hemoglobin A1C or glycosylated hemoglobin)

Secondary

MeasureTime frameDescription
Change in A1C from baseline to week 1212 weeks
Change in FPG from baseline to 24 weeks24 weeksFPG (Fasting plasma glucose)
Change in proportion of subjects with A1C less than or equal to 7.0% at week 2424 weeks
Change in 30 day mean glucose comparing first month to last month after 24 weeks24 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026